Trials temper hopes for proton therapy and weekly cisplatin

· Health

The NRG-GI003 trial found proton therapy did not improve overall survival versus photon therapy in advanced hepatocellular carcinoma and was released early for reporting. Separately, NRG-HN009 found weekly cisplatin did not reduce serious side effects compared with the every-three-weeks regimen in p16-negative head and neck cancer.

Why it matters：Both results challenge assumptions behind costly treatment choices, giving clinicians and payers evidence to reconsider proton referral patterns and cisplatin dosing schedules.

Key points

  • NRG-GI003 compared proton and photon therapy in advanced HCC
  • The trial stopped at planned interim analysis for reporting
  • NRG-HN009 compared weekly versus every-three-week cisplatin with radiation

Sources (original reporting)

More stories from this day